Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
David Gryska
AddedFeb 20, 2024
UpdatedMay 31, 2026
David Gryska

David Gryska

Board Member, Seagen

CrunchbaseLinkedIn

David Gryska's Career

Seagen
Seagen

Bothell, WA, US

Board Member· Board
Forte Biosciences
Forte Biosciences

Dallas, TX, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

David Gryska's Career

Seagen
Seagen
Public$1.7B3.3k1997Bothell, WA, US
Board Member· Board

Leadership at Seagen

Clay SiegallClay SiegallFounder
David R EpsteinDavid R EpsteinBoard Member
Ted LoveTed LoveBoard Member
Felix BakerFelix BakerBoard Member
Daniel WelchDaniel WelchBoard Member
Forte Biosciences
Forte Biosciences
Public$70.8M752007Dallas, TX, US
Board Member· Board

Leadership at Forte Biosciences

Harry GruberHarry GruberCo-Founder
Steven A KornfeldSteven A KornfeldBoard Member
Barbara FinckBarbara FinckBoard Member
A. Paul WagnerA. Paul WagnerCo-Founder

Similar to Forte Biosciences

Fortis BiosciencesFortis BiosciencesCollege Station, TX, USBiologic Therapeuticsest. 2013Fortis BiosciencesCollege Station, TX, US · est. 2013

Fortis: A microbiome startup pioneering in biologic therapeutics through precise biomolecular research.

Angel · $5k1
Fortress BiotechFortress BiotechNew York City, NY, USDermatology, Pharmaceuticalsest. 2006Fortress BiotechNew York City, NY, US · est. 2006

NYC-based Journey Medical Corp. develops and commercializes dermatological pharmaceutical products in the US.

Public · $196.8M187
EquilliumEquilliumLos Angeles, CA, USBiotechnologyest. 2017EquilliumLos Angeles, CA, US · est. 2017

Equillium, Inc.: A clinical-stage biotech firm in California, innovating solutions for autoimmune and inflammatory disorders.

Public · $85M45
Fortis TherapeuticsFortis TherapeuticsSan Diego, CA, USAntibody Drug Therapiesest. 2016Fortis TherapeuticsSan Diego, CA, US · est. 2016

Fortis Therapeutics, a biotech firm, develops innovative antibody drug therapies for advanced cancers.

Series A · $58M75

David Gryska's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to David Gryska

Jim DiStasioJim DiStasioBoard Member · EMCJohn W McCulloughJohn W McCulloughBoard Member · First United BankRahul ChakrabartyRahul ChakrabartyCo-Founder · MyDatingTreeAlex CosmasAlex CosmasCo-Founder · glintBen TrowbridgeBen TrowbridgeBoard Member · Beyond Capital FundTeddy ChaTeddy ChaCEO · PulseData